Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
2.615
+0.015 (0.58%)
Nov 22, 2024, 4:00 PM EST - Market closed
Inventiva Revenue
Inventiva had revenue of 2.73M EUR in the half year ending June 30, 2024, a decrease of -19.40%. This brings the company's revenue in the last twelve months to 19.28M, down -12.56% year-over-year. In the year 2023, Inventiva had annual revenue of 23.16M with 23.12% growth.
Revenue (ttm)
19.28M EUR
Revenue Growth
-12.56%
P/S Ratio
n/a
Revenue / Employee
156,707 EUR
Employees
123
Market Cap
221.31M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 23.16M | 4.35M | 23.12% |
Dec 31, 2022 | 18.81M | 10.31M | 121.32% |
Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
Dec 31, 2019 | 11.29M | 3.91M | 53.02% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Inogen | 331.52M |
Amarin Corporation | 241.02M |
biote | 193.06M |
Utah Medical Products | 44.08M |
Zentalis Pharmaceuticals | 40.56M |
Orchestra BioMed Holdings | 2.65M |
Sera Prognostics | 94.00K |
IVA News
- 2 days ago - Inventiva reports 2024 Third Quarter Financial Information¹ - GlobeNewsWire
- 3 days ago - Combined General Meeting of December 11, 2024 - Availability of the preparatory documents - GlobeNewsWire
- 5 days ago - Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams - Business Wire
- 8 days ago - Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session - GlobeNewsWire
- 24 days ago - Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH - GlobeNewsWire
- 4 weeks ago - Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024 - GlobeNewsWire
- 5 weeks ago - Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants - GlobeNewsWire
- 5 weeks ago - Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday? - Benzinga